A novel series of 2-substituted mercapto-3-(3,4,5-trimethoxybenzyl)-4(3H)-quinazolinones 1-20 was synthesised and evaluated for in vitro antitumour activity. N-(4-Chlorophenyl)-2- [(3-(3,4,5-trimethoxybenzyl)-4(3H)-quinazolinon-2-yl)thio)acetamide (7) and N-(3,4,5 trimethoxybenzyl)-2-[(3-(3,4,5-trimethoxybenzyl)-4(3H)-quinazolinon-2-yl)thio]propanamide (19) exhibited excellent antitumour properties, with mean growth inhibitory concentration (GI 50 ) of 17.90 and 6.33 mM, respectively, compared with those of 5-fluorouracil 5-FU, gefitinib, and erlotinib (mean GI 50 : 18.60, 3.24, and 7.29 mM, respectively). Comparison of the GI 50 (mM) values of compounds 7 and 19 versus those of 5-FU, gefitinib, and erlotinib against an in vitro subpanel of tumour cells lines showed that compounds 7 and 19 have activities almost equal to or higher than that of those standard drugs, especially against lung, CNS, and breast cancer cells. However, compounds 5, 10, 14, 15, 16, 17, and 20 exhibited effective antitumour activity against the different cell lines tested, with growth inhibition percentage (MGI%) of 19, 24, 19, 17, 16, 15, and 16, respectively. A modelling study was performed for compounds 7 and 19 by docking them into the EGFR kinase enzyme to study their mode of binding with the putative binding site.
Introduction
Cancer refers to an abnormal growth of cells, and is the second leading cause of death worldwide 1 . Several of the current therapeutic agents have numerous side effects caused by their nonselective activity; therefore, the synthesis of safe and selective agents with a high therapeutic index is a vital research area. Quinazolinone nucleus is a characteristic bioactive scaffold present in several critical agents of biological interest . Gefitinib and erlotinib ( Figure 1 ) are known to contain a quinazoline nucleus and are effective in the treatment of breast and non-small cell lung (NSL) cancer via inhibition of epidermal growth factor receptor-tyrosine kinase (EGFR-TK) 30, 31 . EGFR is over-expressed in numerous human tumours such as prostate, ovarian, breast, colon, and renal [31] [32] [33] [34] . In our previously published studies 10, 11, 15, 18, 19 , the 2-mercaptoquinazoline analogue containing trimethoxyphenyl moiety showed significant antitumour activity such as 2-[(3-benzyl-6,7-dimethoxy-4(3H)-quinazolinon-2-yl)thio]-N-(3,4,5-trimethoxyphenyl)acetamide (A; GI 50 ¼ 7.24 mM), 2-[(3-benzyl-6-methyl-4(3H)-quinazolinon-2-yl)thio]-N-(3,4,5-trimethoxyphenyl)acetamide (B; GI 50 ¼ 14.12 mM), 2-[(3-phenethyl-4(3H)-quinazolinon-2-yl)thio]-N-(3,4,5-trimethoxyphenyl)acetamide (C; GI 50 ¼ 3.16 mM), 3-[(3-benzyl-6-methyl-4(3H)-quinazolinon-2-yl)thio]-N- (3,4,5-trimethoxyphenyl) propanamide (D; GI 50 ¼14.12 mM) compared with that of the reference drug 5-fluorouracil (FU; mean GI 50 18 .60 mM; Figure 1 ). In this study, we designed several new 2-substituted mercapto-3-(3,4,5-trimethoxybenzyl)quinazolin-4(3H)-ones containing various alkyl, acetamide, and isopropanamide fragments at position 2 of the quinazoline core, with different electronic environments that would affect lipophilicity. The synthesised molecules 2-20 were evaluated for their in vitro antitumour activities at a single dose (10 mM; Figure 1 ). These hybrids were synthesised with an aim to develop effective and selective antitumour molecules.
Experimental

Chemistry
Melting points were recorded on a Barnstead 9100 electrothermal melting apparatus. IR spectra (KBr) were recorded on an FT-IR Perkin-Elmer spectrometer ( cm À1 ). 1 H and 13 C NMR spectra were recorded on Bruker 500 or 700 MHz spectrometers using DMSO-d 6 as the solvent. Microanalytical data (C, H, and N) were obtained using a Perkin-Elmer 240 analyser and the proposed structures were within ±0.4% of the theoretical values. Mass spectra were recorded on a Varian TQ 320 GC/MS/MS mass spectrometer. Data of compound 8 were collected on a Bruker APEX-II D8 Venture area diffractometer (Billerica, MA), equipped with graphite monochromatic Mo Ka radiation, k ¼ 0.71073 Å at 296 (2) K. Cell refinement and data reduction were carried out by Bruker SAINT. SHELXT 35, 36 was used to solve the structure.
2-Thioxo-3-(3,4,5-trimethoxybenzyl)-2,3-dihydroquinazolin-4(1H)-one (1)
A mixture of 3,4,5-trimethoxybenzyl isothiocyanate (11 mmol, 2.36 g), anthranilic acid (10 mmol, 1.37 g) and triethylamine (15 mmol, 1.51 g), was heated under reflux for 3 h in ethanol (20 ml General procedure for the synthesis of compounds 2-13 A mixture of 2-thioxo-3-(3,4,5-trimethoxybenzyl)-2,3-dihydroquinazolin-4(1H)-one (1) (1 mmol, 358 mg) and appropriate alkylhalides or 2-chloro-N-(substituted)acetamides (1 mmol) in 10 ml acetone containing potassium carbonate (2 mmol, 277 mg) was stirred at room temperature for 10-12 h. The reaction mixture was filtered, the solvent removed, and the obtained solid was washed with water and dried. General procedure for the synthesis of compounds [14] [15] [16] [17] [18] [19] [20] A mixture of 2-thioxo-3-(3,4,5-trimethoxybenzyl)-2,3-dihydroquinazolin-4(1H)-one (1) (1 mmol, 358 mg) and appropriate 2-chloro-N-(substituted)propanamides (1 mmol) in 10 ml acetone containing potassium carbonate (2 mmol, 277 mg) was heated under reflux for 6-9 h. The reaction mixture was filtered while hot, the solvent was removed, and the obtained solid was washed with water and dried. (15) Yield: 82%; mp: 216-217 C; IR (KBr, cm 
X-ray crystallography
Data of compound 8 were collected on a Bruker APEX-II D8 Venture area diffractometer, equipped with graphite monochromatic Mo Ka radiation, k ¼ 0.71073 Å at 296 (2) K. Cell refinement and data reduction were carried out by Bruker SAINT. SHELXT 35, 36 was used to solve the structure. The final refinement was carried out by full-matrix least-squares techniques with anisotropic thermal data for non-hydrogen atoms on F. CCDC 1534954 contains the supplementary crystallographic data for this compound and can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_ request/cif.
Antitumour screening
The antitumour evaluation was performed in nearly 60 human tumour cell lines obtained from nine organs, according to the rules of the Drug Evaluation Branch, NCI, Bethesda, MD [37] [38] [39] [40] [41] .
Docking methodology
All modelling experiments were conducted with MOE 2007.9 of the Chemical Computing Group Inc. (Montreal, Canada) 42, 43 . The starting coordinates of the X-ray crystal structure of the EGFR 
Results and discussion
Chemistry 2-thioxo-3-(3,4,5-trimethoxybenzyl)-2,3-dihydroquinazolin-4(1H)-one (1) was obtained at 86% yield by heating 2-aminobenzoic acid with 3,4,5-trimethoxybenzyl isothiocyanate in ethanol containing triethylamine (Scheme 1). The confirmation of compound 1 exists as thione tautomer in the solid-state according to X-ray of quinazoline analogue 4546, due to the dimeric aggregates are connected into layers by C¼HÁÁÁO interactions, involving the bifurcated carbonyl-O atom, and C-HÁÁÁS interactions 45, 46 . The thione tautomer was confirmed by presence of singlet signal at 13.04ppm, corresponding to NH group and unique signal at 175.6 ppm related to C¼S according to 1 H NMR and 13 C NMR spectra. Additionally, NMR spectra of compound 1 revealed three characteristic signals related to trimethoxybenzyl group at 59.9, 55.8, 48.9, 5.60, 3.72, and 3.68 ppm. Accordingly, compound 1 was stirred at room temperature with various halides (such as methyl iodide, 4-(2-chloroethyl)morpholine, 1-(2-chloroethyl)piperidine, and 4-chlorobenzylchloride) in acetone containing potassium carbonate to give 2-(substituted alkylthio)-3-(3,4,5-trimethoxybenzyl)-quinazolin-4(3H)-ones 2-5 analogues at 88-93% yield (scheme 1). The 1 H NMR spectra of compounds 2-5 showed loss of the NH group of the parent compound at 13.04 ppm, and a new signal related to s-alkyl moiety was observed at 4.61-2.62 ppm in the 1 H NMR spectra and at 14.7-35.8 ppm in the 13 C NMR spectra of these compounds.
Compound 1 was also stirred with various 2-chloro-N-(substituted)acetamides and 2-chloro-N-(substituted)propanamides in acetone containing potassium carbonate to give N-(substituted)-2- groups of the parent quinazoline moiety at 47.1-59.9 and 160.6-160.8, respectively.
X-ray crystallography
The crystallographic data and refinement information of compound 8 are summarised in Tables S1-S3. The asymmetric unit is comprised of one independent molecule as shown in Figures S1 and S2. All the bond lengths and angles are in normal ranges 47 . In the crystal structure, the central quinazolin-4(3H)-one plane makes dihedral angles of 62.97 and 68.48 with the trimethoxybenzyl and flurophenyl groups, respectively, in different directions. The crystal packing was formed by three intermolecular interactions between N 3 ¼H 1 N 3 ···O 2 , C 9 ¼H 9 A···O 1 , and C 9 ¼H 9 B···O 2 with bond lengths 2.07 (3), 2.35, and 2.31 Å and bond angles 158 (3) , 143 , and 144
, respectively.
Antitumour activity
Evaluation of the in vitro antitumour activity of the new synthesised compounds indicated in Table 1 (Table 1) . Conversely, compounds 3, 6, 12, and 13 showed weak activities against the tested cell lines with PCE of 7/55, 8/57, 6/56, and 9/57, respectively (Table 1) (Table 1) .
N-(Substituted)-2-[(3-(3,4,5-trimethoxybenzyl)-4(3H)-quinazolinon-2-yl)thio]acetamides 7-13 showed mild to potent antitumour activities with MGI % ranging from 7 to 47, while N-(substituted)-2-[(3-(3,4,5-trimethoxybenzyl)-4(3H)quinazolinon-2-yl)thio]propanamides 14-20 showed potent antitumour activities with MGI % ranging from 10 to 65 (Table 1) . Compounds 3, 4, 6, 8, 11, 12 , and 13 showed selective activity against different cancer cell lines. Compounds 3, 4, 11, 12, and 13 showed selective activity against the NCI-H522 cancer cell line, with a range of growth inhibition percentage (RGI %) of 17-32, while compounds 3, 6, 11, and 12 had selectivity against the UO-31 cancer cell line with RGI % of 25-32. The SNB-75 cancer cell line was sensitive to compounds 4, 11, and 12 with RGI % of 21-27, whereas the MDA-MB-468 cancer cell line was sensitive to compounds 11 and 13 with RGI % of [16] [17] [18] [19] . The A498 cancer cell line was sensitive to compounds 6 and 11 with RGI % of 18-20, while the K-562, NCI-H226, UACC-62, and MDA-MB-231/ATCC cancer cell lines were susceptible to compound 11 with RGI % of 19-34. The MOLT-4, OVCAR-4, and SF-268 cancer cell lines were susceptible to compounds 3, 4, and 13 with RGI % of 17-30. The prostate cancer cell line PC-3 showed selective sensitivity to compounds 2, 5, 7, and 14-18 with RGI % of 18-51; whereas compounds 7 and 19 showed selective activities with RGI % of 34-42 against the DU-145 prostate cell line (Table 1) .
Furthermore, compounds 2, 5, 7, 9, 10, and 14-20 showed potent activity against leukaemia, NSL cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, and breast cancer cell lines with RGI % of 12-92, 16 ->100, 18-88, 13 ->100, 16 ->100, 16-83, 16 ->100, and 14-99, respectively ( Table 1) .
The MGI% data revealed that compounds 7 and 19 were the most active, with antitumour activity against numerous cell lines belonging to diverse tumour subpanels (Table 1) . Therefore, these compounds were tested against a panel of 57 tumour cell lines at a 5-log dose range [37] [38] [39] [40] [41] and the median growth inhibitory (GI 50 ), total growth inhibitory (TGI), and median lethal (LC 50 ) concentrations were calculated for each cell line ( (Table 2) .
Additionally, comparing the median GI 50 values (mM) of compounds 7 and 19 with those of 5-FU, gefitinib, and erlotinib against an in vitro subpanel of tumour cell lines showed that compounds 7 and 19 had activities almost equal to or higher than these known drugs against most cell lines (Table 3) .
Structure-activity relationships
Structure activity relationships for antitumour activities with MGI % indicated that (i) 2-benzylmercapto-4(3H)-quinazolinone 5 showed higher antitumour activity (MGI%: 19%) than did the 2-alkylmercapto-4(3H)-quinazolinone derivatives such as compounds 2-4 (MGI%: 2-11%); (ii) N-(substituted phenyl)-2-[(3-(3,4,5-trimethoxybenzyl)-4(3H)-quinazolinon-2-yl)thio]acetamide analogues 
Molecular docking results
EGFR are tyrosine kinase enzymes that are overexpressed in numerous tumours such as colon, prostate, breast, ovarian, renal, and NSL cancers [31] [32] [33] [34] 48 . The inhibition of tyrosine kinase by quinazoline derivatives such as gefitinib and erlotinib (Figure 1 ) is well documented 30, 31 . Accordingly, the antitumour activity of the target compounds against colon, prostate, breast, ovarian, renal, and NSL cancers encouraged us to study the molecular docking of the compounds into the putative binding site on EGFR kinase. In this study, the most active compounds 7 (mean GI 50 : 17.90 mM) and 19 (mean GI 50 :6.33 mM) were docked into the putative active site of EGFR kinase, as well as the reference inhibitor erlotinib (mean GI 50 : 7.29 mM) 44 . All docking calculations were performed using MOE 2007.09 software (MOE of Chemical Computing Group Inc., Montreal, Canada) 42 . The binding energies of the docked compounds 7, 19, and erlotinib (PDB code; 1M17) 44 into the putative binding site of EGFR were À22.11, À25.21, and À26.99 kcal/mol, respectively (Figure 2 ). The molecular docking of the most active compound 19 revealed that it had similar orientation to erlotinib inside the receptor pocket, as well as additional bonding interactions. The docking results showed six typical and atypical hydrogen bonds with surrounding amino acids as shown in Figure 2 . The trimethoxybenzyl fragment at C-3 of the quinazoline core formed bifurcated hydrogen bonds with amino acids Lys 721 . Moreover, the 4-quinazolinone ring uniquely formed two hydrogen bonds with the distinctive residues Met 769 and Thr 766 , similar to that observed in erlotinib (Figure 2) . Additionally, the carbonyl group of the acetanilide fragment of compound 19 formed bifurcated hydrogen bonds with the amino acid residue Cys 773 and Gly 772 augmenting the recognition within the enzyme binding site ( Figure 2 and Table 4 ).
Similar to compound 19, compound 7 binds with four hydrogen bonds. It was found that the trimethoxybenzyl group at C-3 of the quinazoline core was clearly recognised with hydrogen bonding to the amino acid residue Lys 721 similar to compound 19, while the quinazoline core was shifted away from the distinctive amino acid residue Met 769 (Figure 2) . Additionally, two hydrogen bonds with the amino acid residue Gly 772 and the distinctive residue Thr 766 were found ( Figure 2 ). It is obvious that the molecular docking results can be used to design novel quinazoline derivatives with potential binding to EGFR kinase and antitumour activity (Table 4) . (GI 50 : 22.60 mM, TGI: 100 mM, and LC 50 : 100 mM). Comparing the median GI 50 (mM) of 5-FU, gefitinib, and erlotinib with that of compounds 7 and 19 showed that compounds 7 and 19 showed antitumour activities almost equal to or higher than that of the known drugs against most subpanel tumour cell lines. A molecular docking study for compounds 7 and 19 into the ATP binding site of EGFR-TK showed similar binding as that of erlotinib.
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